- Home
- ANL vs MIST Comparison
ANL vs MIST Comparison
Compare ANL & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- MIST
- Stock Information
- Founded
- ANL 2004
- MIST 2003
- Country
- ANL Cayman Islands
- MIST Canada
- Employees
- ANL N/A
- MIST N/A
- Industry
- ANL
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- MIST Health Care
- Exchange
- ANL Nasdaq
- MIST Nasdaq
- Market Cap
- ANL 84.5M
- MIST 100.3M
- IPO Year
- ANL 2023
- MIST N/A
- Fundamental
- Price
- ANL $2.14
- MIST $1.80
- Analyst Decision
- ANL Strong Buy
- MIST Strong Buy
- Analyst Count
- ANL 2
- MIST 3
- Target Price
- ANL $9.00
- MIST $13.00
- AVG Volume (30 Days)
- ANL 9.6K
- MIST 372.6K
- Earning Date
- ANL 08-08-2024
- MIST 11-12-2024
- Dividend Yield
- ANL N/A
- MIST N/A
- EPS Growth
- ANL N/A
- MIST N/A
- EPS
- ANL N/A
- MIST N/A
- Revenue
- ANL $5,000,000.00
- MIST N/A
- Revenue This Year
- ANL N/A
- MIST N/A
- Revenue Next Year
- ANL N/A
- MIST N/A
- P/E Ratio
- ANL N/A
- MIST N/A
- Revenue Growth
- ANL N/A
- MIST N/A
- 52 Week Low
- ANL $1.85
- MIST $1.12
- 52 Week High
- ANL $17.48
- MIST $2.93
- Technical
- Relative Strength Index (RSI)
- ANL 43.45
- MIST 49.60
- Support Level
- ANL $2.23
- MIST $1.76
- Resistance Level
- ANL $2.44
- MIST $1.86
- Average True Range (ATR)
- ANL 0.19
- MIST 0.10
- MACD
- ANL -0.01
- MIST -0.02
- Stochastic Oscillator
- ANL 23.43
- MIST 18.93
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).